Bristol-Myers Squibb Company stock price, BMY

Bristol-Myers Squibb Company stock chart:



Bristol-Myers Squibb Company close price: 55.03

Stock price forecast:

DOWN TO -0.15%
Target: 54.95

Total forecasts: 84
Reached: 9 (10.71%)

Total Win: 16.33 (30.84%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
9085910.59%16.330.36%4,167.884.340.10%20.670.45%
303100.00%0.000.00%1,705.930.000.00%0.000.00%
141500.00%0.000.00%825.450.000.00%0.000.00%
7800.00%0.000.00%440.240.000.00%0.000.00%

Showing 1-10 of 470 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-06-2655.0354.950000-00-00
2017-06-2555.0354.950000-00-00
2017-06-2455.0354.950000-00-00
2017-06-2355.0354.950000-00-00
2017-06-2255.0355.130000-00-00
2017-06-2155.0355.120000-00-00
2017-06-2055.0355.190000-00-00
2017-06-1955.0355.120000-00-00
2017-06-1855.0355.190000-00-00
2017-06-1755.0355.190000-00-00

Bristol-Myers Squibb Company latest news:


  • 06/13/2017 14:09:51

    BRIEF-Bristol-Myers Squibb declares quarterly dividend of $0.39/shr

    * Bristol-Myers Squibb Co says declared a quarterly dividend of $0.39 per share on $.10 par value common stock of corporation Source text for Eikon: Further company coverage:

  • 06/05/2017 14:24:26

    BRIEF-Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer

    Bristol-myers Squibb Co(BMY). * Bristol-Myers Squibb(BMY) announces new collaboration to evaluate combination therapy in colorectal cancer. * Entered into a clinical research collaboration with Novartis Source text for Eikon: Further company coverage:

  • 04/21/2017 12:19:56

    BRIEF-Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer

    * Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo (Nivolumab) for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

  • 04/03/2017 09:07:05

    Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial

    Bristol-Myers Sqibb Co. said Monday morning that the combination of its two cancer drugs showed the best survival rates in melanoma patients in a late-stage clinical trial. The combination of the drugs Opdivo and Yervoy is one many Wall Street analysts believe is promising. Two-year overall survival rates for patients with previously untreated advanced melanoma were highest for the combination treatment, or 64%, followed by 59% for Opdivo alone and 45% for Yervoy alone, according to the company. The phase 3 trial enrolled 945 patients, and had a minimum follow-up period of 28 months. Bristol-Myers said that the clinical trial was not designed to compare Opdivo in combination with Yervoy with Opdivo alone, but that analyses found a relative reduction in death risk of 12% for the combination treatment, with risk of death reduced especially for patients with the PD-L1 biomarker of less than 1%. That's an important distinction, said EvercoreISI analyst Umer Raffat, who said the findings could have implications for an ongoing lung cancer trial. "Could the [Opdivo and Yervoy] combo have a better shot in the

  • More trends:

    Bristow Group IncBRS | Brixmor Property Group Inc.BRX | Broadridge Financial SolutionsBR | Brookdale Senior Living Inc.BKD | Brookfield Asset Management IncBAM | Brookfield Canada Office PropertiesBOXC | Brookfield DTLA Inc.DTLA^ | Brookfield Global Listed Infrastructure Income FunINF | Brookfield High Income Fund Inc.HHY | Brookfield Infrastructure Partners LPBIP |